Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells
Our state-of-the-art clinic, compassionate staff, and proven therapies are ready to help you heal and thrive once again
For people who want maximum simplicity, Retatrutide alone delivers extraordinary results
Manufacturer savings programs from Novo Nordisk can reduce out-of-pocket costs for eligible patients
A triple-peptide combination of BPC-157, TB-500, and GHK-Cu targeting complementary angiogenic, cellular migration, and extracellular matrix remodeling pathways in preclinical research
What makes BPC-157 particularly interesting from a research standpoint is its apparent ability to act on multiple healing pathways simultaneously including angiogenesis, fibroblast activity, collagen synthesis, and growth factor regulation
